EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach

Matteo Fassan, Takeshi Kuwata, Kristina A Matkowskyj, Christoph Röcken, Josef Rüschoff

Modern Pathology · 2024-11 · 37 (11) · 100589

DOI: 10.1016/j.modpat.2024.100589 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Modern Pathology, 2024-11. Verfasst von Matteo Fassan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy. El…. Hauptthemen laut MEDLINE: Adenocarcinoma, Biomarkers, Tumor, Claudins, Esophageal Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin-18.2 (CLDN18.2) expression evaluated by immunohistochemistry is a new biomarker for gastric and gastroesophageal junction adenocarcinomas that will soon have market authorization for implementation into routine clinical practice. Despite successful testing in the setting of clinical trials, no specific practical testing guidelines have been proposed. Several preanalytical and analytical variables may interfere with adequate CLDN18.2 staining interpretation; thus, this article provides practical guidance on CLDN18.2 testing and scoring in gastric and gastroesophageal junction adenocarcinomas to identify patients who may respond to targeted therapy with monoclonal antibodies directed against CLDN18.2. Based on available data, moderate to strong (2+/3+) membrane staining in ≥75% of adenocarcinoma cells is the proposed cutoff for clinical use of monoclonal antibody anti-CLDN18.2 (zolbetuximab).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaBiomarkers, TumorClaudinsEsophageal NeoplasmsEsophagogastric JunctionImmunohistochemistryStomach NeoplasmsHumansAntibodies, MonoclonalMolecular Targeted Therapy

Stichwörter der Autor:innen

CLDN18.2gastric cancerimmunohistochemistrypredictive biomarkers

Substanzen

Antibodies, MonoclonalBiomarkers, TumorClaudinsCLDN18 protein, humanzolbetuximab

Autor:innen und Institutionen

  • Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy. Electronic address: matteo.fassan@unipd.it.
  • Department of Genetic Medicine and Services, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Pathology, University-Hospital Schleswig-Holstein (UKSH), Kiel, Germany.
  • Discovery Life Sciences Biomarker Services, Kassel, Germany.

Zitieren

APA

Fassan, M., Kuwata, T., Matkowskyj, K. A., Röcken, C., & Rüschoff, J. (2024). Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Modern Pathology, 37(11), 100589. https://doi.org/10.1016/j.modpat.2024.100589

Vancouver

Fassan M, Kuwata T, Matkowskyj KA, Röcken C, Rüschoff J. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Modern Pathology. 2024;37(11):100589. doi:10.1016/j.modpat.2024.100589

BibTeX
@article{Fassan2024,
  author = {Fassan, Matteo and Kuwata, Takeshi and Matkowskyj, Kristina A and Röcken, Christoph and Rüschoff, Josef},
  title = {Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach},
  journal = {Modern Pathology},
  year = {2024},
  volume = {37},
  number = {11},
  pages = {100589},
  doi = {10.1016/j.modpat.2024.100589}
}
Kostenlos starten →